Komori
Other Disclosures206APRISM BioLab Co.,LTDPharmaceuticals

Eisai Publishes Paper on Human Pharmacokinetic Analysis of E7386 Using a Microtracer Study; E7386 Was Jointly Discovered by PRISM BioLab and Eisai

A paper on a pharmacokinetic study in healthy adults of E7386, an antineoplastic drug jointly created by PRISM BioLab and Eisai Co.,Ltd., has been published in a peer-reviewed academic journal. The study quantitatively evaluated the absorption, metabolism and excretion of E7386 by combining oral administration with intravenous microtracer administration.

Worth reading
57In focus
Scored from 5 of 6 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
23.6
Geometric mean absolute bioavailability (%)
Wording
Definitive
How definitive the wording is.

Announced details

E7386
Applicable field (uses covered by this announcement)

Antineoplastic drug; monotherapy and combination therapy with other anticancer drugs for solid tumors

What the company reported numerically
Quantitative Effects

Geometric mean absolute bioavailability of 23.6% (CV% 34.6); 87.9% of administered radioactivity was recovered, with 85.1% excreted in feces

Relationship between the counterparty and the company
PRISM BioLab Co.,LTD206A
Relationship with the Company

PRISM BioLab and Eisai Co.,Ltd. jointly created E7386.

CounterpartyEisai Co.,Ltd.

Head office: Bunkyo-ku, Tokyo. Other company information: Not disclosed.

Registration number and expiry date

DOI: 10.1002/jcph.70202. Clinical trial registration numbers: NCT03264664, NCT03833700, NCT04008797.

Location (as indicated in this announcement)

Shonan iPark, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

The Journal of Clinical Pharmacology 2026; 66(5): e70202

Announced details
ItemDetails
Names of Products / Services CoveredE7386
CounterpartyEisai Co.,Ltd.
Counterparty overviewHead office: Bunkyo-ku, Tokyo. Other company information: Not disclosed.
Relationship with the CompanyPRISM BioLab and Eisai Co.,Ltd. jointly created E7386.
Applicable areaAntineoplastic drug; monotherapy and combination therapy with other anticancer drugs for solid tumors
Registration number and expiry dateDOI: 10.1002/jcph.70202. Clinical trial registration numbers: NCT03264664, NCT03833700, NCT04008797.
LocationShonan iPark, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa
Quantitative EffectsGeometric mean absolute bioavailability of 23.6% (CV% 34.6); 87.9% of administered radioactivity was recovered, with 85.1% excreted in feces
SourceThe Journal of Clinical Pharmacology 2026; 66(5): e70202
Items this document does not state (9)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyLocation scaleUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To quantitatively characterize the pharmacokinetics and disposition of E7386 and obtain insights for its ongoing clinical development.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Eisai Publishes Paper on Human Pharmacokinetic Analysis of E7386 Using a Microtracer Study; E7386 Was Jointly Discovered by PRISM BioLab and Eisai | PRISM BioLab Co.,LTD (206A) timely disclosure | Komori